Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
Pharmacologic Treatments for Sleep Disorders in Children: A Systematic Review
Marian S McDonagh1, Rebecca Holmes1, Frances Hsu1
11 Department of Medical Informatics and Clinical Epidemiology, Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Portland, OR, USA.
Insights
Melatonin effectively improves sleep in children with neurodevelopmental disorders, offering short-term benefits for sleep latency and duration. Other medications show limited efficacy for pediatric sleep issues.
Area of Science:
- Pediatric Sleep Medicine
- Neurodevelopmental Disorders Pharmacology
- Clinical Trial Analysis
Background:
- Sleep problems are prevalent in children, particularly those with neurodevelopmental disorders, impacting behavior and quality of life.
- Pharmacologic interventions are often considered for pediatric sleep disorders, necessitating evidence-based efficacy and safety data.
Purpose of the Study:
- To systematically review the efficacy and harms of pharmacologic treatments for sleep disorders in children and adolescents.
- To evaluate specific medications including zolpidem, eszopiclone, diphenhydramine, and melatonin.
Main Methods:
- Systematic review of 22 placebo-controlled randomized controlled trials (RCTs) published through June 2018.
- Searches conducted in MEDLINE, Cochrane Library, and PsycINFO databases.
- Included 1758 children and adolescents (mean age 8.2 years) across trials ranging from 1 to 13 weeks.
Main Results:
- Zolpidem and eszopiclone showed no sleep improvement in children with attention-deficit/hyperactivity disorder (ADHD), though zolpidem improved Clinical Global Impression scores.
- Diphenhydramine demonstrated minor improvements in sleep latency and duration (8-10 minutes) in a small RCT.
- Melatonin significantly improved sleep latency (median 28 min) and duration (median 33 min) in 19 RCTs, particularly in children with autism spectrum disorder (ASD) and neurodevelopmental disorders.
- Adverse events were infrequent with melatonin but more common with eszopiclone and zolpidem.
Conclusions:
- Melatonin is a useful short-term treatment for specific sleep outcomes in children, especially those with comorbid ASD and neurodevelopmental disorders.
- Current evidence for zolpidem, eszopiclone, and diphenhydramine in pediatric sleep disorders is limited or shows minimal benefit.
- Further research is needed to adequately study other pharmacologic interventions and long-term outcomes for pediatric sleep disorders.
Abstract:
Sleep problems are common in children, especially those with neurodevelopmental disorders, and can lead to consequences in behavior, functioning, and quality of life. We systematically reviewed the efficacy and harms of pharmacologic treatments for sleep disorders in children and adolescents. We searched MEDLINE, Cochrane library databases, and PsycINFO through June 2018. We included 22 placebo-controlled randomized controlled trials (1-13 weeks' duration), involving 1758 children (mean age 8.2 years). Single randomized controlled trials of zolpidem and eszopiclone in children with attention-deficit/hyperactivity disorder (ADHD) showed no improvement in sleep or ADHD ratings. Clinical Global Impression Improvement/Severity scores significantly improved with zolpidem ( P = .03 and P = .006, respectively). A single, small randomized controlled trial of diphenhydramine reported small improvements in sleep outcomes (8-10 minutes' better sleep latency and duration) after 1 week. In 19 randomized controlled trials, melatonin significantly improved sleep latency (median 28 minutes; range 11-51 minutes), sleep duration (median 33 minutes; range 14-68 minutes), and wake time after sleep onset (range 12-43 minutes), but not number of awakenings per night (range 0-2.7). Function and behavior improvement varied. Improvement in sleep was greatest in children with autism or other neurodevelopmental disorders, and smaller in adolescents and children with chronic delayed sleep onset. Adverse events were infrequent with melatonin, but more frequent than placebo in children taking eszopiclone or zolpidem. These findings show that melatonin was useful in improving some sleep outcomes in the short term, particularly those with comorbid ASD and neurodevelopmental disorders. Other drugs and outcomes are inadequately studied.
Related Concept Videos
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
REM Sleep Behavior Disorder
RBD is significantly associated with...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...

